News | November 14, 2022
Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Subscribe To Our Newsletter & Stay Updated
